Navigation Links
Agilux Laboratories Announces the Launch of GLP LC/MS/MS Bioanalytical Services
Date:1/25/2010

Expanded GLP bioanalytical testing services makes Agilux the largest bioanalytical CRO in New England.

Worcester, MA (PRWEB) January 25, 2010 -- Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides bioanalytical and in vitro ADMET services for the biotechnology and pharmaceutical industries, has launched GLP compliant LC/MS/MS bioanalytical services supporting nonclinical and clinical studies.

Founded in 2007, Agilux has grown into the largest bioanalytical contract laboratory in New England by focusing on high quality, rapid turnaround services for discovery support. Agilux can now deliver the same high quality, rapid turnaround services to support GLP compliant nonclinical and clinical studies.

The "green field" start of the GLP LC/MS/MS bioanalytical service has allowed Agilux to incorporate the very latest technology with many novel, innovative approaches. The management team's extensive knowledge and experience in the GLP bioanalytical environment result in novel, efficient processes that are fully compliant with the latest regulations. With renowned customer service, Agilux is focused on delivering "Better Data Faster"

"At Agilux, we have challenged ourselves to innovate to the advantage of our clients. Our highly successful Discovery 2.0 has demonstrated that there was room to innovate in the discovery bioanalytical services space. In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service" said Jim Jersey, president and CEO at Agilux.

About Agilux Laboratories, Inc.

Agilux Laboratories, Inc. is a contract research organization (CRO) focused on bioanalytical and PK/PD testing services for the biotech and pharmaceutical industries. Leveraging industry and contract research experience of its management team, the company delivers high quality bioanlaytical chemistry and PK/PD data more rapidly. Agilux helps clients make better decisions during drug discovery and development by providing quality data earlier in the research process by using technologies and systems that increase turnaround speed well beyond industry standards. Founded in 2007 by industry veterans Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in Worcester, MA, and is funded by private equity firm Ampersand Ventures. For more information, call 508-753-5000. Online at www.agiluxlabs.com.

Contact:
Steve Guyan
Vice President, Sales and Marketing
(508)-762-4402

# # #

Read the full story at http://www.prweb.com/releases/GLPBioanalytical/AgiluxLabs/prweb3495654.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
2. Underwriters Laboratories Announces Alternative Certification Program for Lead Free Verification of Cooking and Plumbing Products
3. Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry
4. Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
5. Renewal Laboratories(TM) Announces the First Omega3 Supplement Water for Cardiac Health
6. Reportlinker Adds Whos Doing What in Molecular Diagnostics? - Kalorama / Emmes Survey of US Laboratories Report
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
9. ARUP Laboratories Scientist Tanya Sandrock Receives NIH Grant to Search for Additional HIV Therapies
10. Care-Tech Laboratories Agrees to Stop Making, Selling and Distributing Unapproved Antimicrobial Products
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: